Cardiff Oncology Inc (CRDF) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Cardiff Oncology Inc stock (CRDF) is currently trading at $1.73. Cardiff Oncology Inc PS ratio (Price-to-Sales) is 207.52. Analyst consensus price target for CRDF is $7.75. WallStSmart rates CRDF as Sell.
- CRDF PE ratio analysis and historical PE chart
- CRDF PS ratio (Price-to-Sales) history and trend
- CRDF intrinsic value — DCF, Graham Number, EPV models
- CRDF stock price prediction 2025 2026 2027 2028 2029 2030
- CRDF fair value vs current price
- CRDF insider transactions and insider buying
- Is CRDF undervalued or overvalued?
- Cardiff Oncology Inc financial analysis — revenue, earnings, cash flow
- CRDF Piotroski F-Score and Altman Z-Score
- CRDF analyst price target and Smart Rating
Cardiff Oncology Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Cardiff Oncology Inc (CRDF) · 7 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in revenue growth. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Cardiff Oncology Inc (CRDF) Key Strengths (1)
Revenue surging 60.90% year-over-year
Supporting Valuation Data
Cardiff Oncology Inc (CRDF) Areas to Watch (6)
Company is destroying shareholder value
Losing money on operations
Very expensive at 207.5x annual revenue
Micro-cap company with very limited liquidity and high volatility
Fairly priced relative to book value
Moderate institutional interest at 36.89%
Supporting Valuation Data
Cardiff Oncology Inc (CRDF) Detailed Analysis Report
Overall Assessment
This company scores 27/100 in our Smart Analysis, earning a F grade. Out of 7 metrics analyzed, 1 register as strengths (avg 10.0/10) while 6 fall into concern territory (avg 2.8/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Revenue Growth. Growth metrics are encouraging with Revenue Growth at 60.90%.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Price/Sales. Some valuation metrics including Price/Sales (207.52), Price/Book (2.71) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -71.50%, Operating Margin at -3221.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -71.50% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 60.90% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
CRDF Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
CRDF's Price-to-Sales ratio of 207.52x trades at a deep discount to its historical average of 732.38x (29th percentile). The current valuation is 97% below its historical high of 6035.81x set in Nov 2020, and 515% above its historical low of 33.75x in May 2018.
WallStSmart Analysis Synopsis
Data-driven financial summary for Cardiff Oncology Inc (CRDF) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Cardiff Oncology Inc is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 593,000 with 61% growth year-over-year.
Key Findings
Revenue growing at 61% YoY, reaching 593,000. This pace significantly outperforms most BIOTECHNOLOGY peers.
Debt-to-equity ratio of 0.02 indicates a conservative balance sheet with 10M in cash.
Free cash flow is -6M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can Cardiff Oncology Inc maintain 61%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Cardiff Oncology Inc.
Bottom Line
Cardiff Oncology Inc is a high-conviction growth story with revenue accelerating at 61% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin 0.0% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Cardiff Oncology Inc(CRDF)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops drugs for the treatment of cancer. The company is headquartered in San Diego, California.